#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
As medicinal cannabis prescribing increases in Australia, clinicians need clear evidence-based guidance and institutional support to safely counsel patients on efficacy, dosing, and drug interactions for specific conditions. The establishment of the Cannabinoid Clinical and Research Excellence centre addresses a critical gap by consolidating research and best practices, enabling clinicians to move beyond anecdotal reports to evidence-informed prescribing decisions. Patients benefit when their clinicians have access to standardized training and reliable information rather than navigating conflicting claims about cannabis safety and therapeutic benefit.
Australia’s medicinal cannabis sector is expanding rapidly following regulatory approval, but the healthcare system lacks adequate infrastructure and expertise to manage this growth effectively, as evidenced by the establishment of the Cannabinoid Clinical and Research Excellence (ACRE) center with NHMRC funding to address knowledge gaps. The mainstream adoption of cannabis-based medicines has outpaced clinician training, standardized prescribing protocols, and quality assurance mechanisms, creating challenges in ensuring safe and evidence-based patient care across the country. Without sufficient clinical guidance and research capacity, Australian practitioners face barriers to appropriate patient selection, dosing, and monitoring of cannabis therapies, while patients may encounter inconsistent care quality and access disparities. The ACRE initiative represents an attempt to systematize knowledge and establish best practices, but resource constraints and the nascent state of medicinal cannabis medicine suggest that many clinicians remain underprepared to manage this therapeutic option. For Australian clinicians and patients, the key takeaway is that while medicinal cannabis is now legally available, accessing treatment through informed practitioners supported by robust clinical standards remains a work in progress, making engagement with emerging evidence-based centers and protocols essential until broader expertise develops.
“We have more patients asking about cannabis than we have evidence to guide them, and that’s the real clinical problem we’re facing right now. Australia’s investment in ACRE is exactly what we need because without rigorous research infrastructure, we’re essentially asking physicians to prescribe based on anecdote rather than pharmacology, which ultimately fails our patients.”
💊 As medicinal cannabis access expands across Australia through regulatory pathways like the Special Access Scheme, clinicians increasingly encounter patients seeking or already using these products for conditions ranging from chronic pain to epilepsy. While the establishment of dedicated research centers signals growing institutional recognition of cannabinoids’ therapeutic potential, the current evidence base remains heterogeneous, with robust data limited to specific indications such as chemotherapy-induced nausea and certain seizure disorders. The gap between patient demand, regulatory availability, and clinical evidence creates a challenging landscape where providers must weigh potential benefits against incomplete safety and efficacy profiles, uncertain dosing standards, and variable product quality. Clinicians should approach medicinal cannabis discussions with informed curiosity rather than dismissal, document their reasoning for any prescribing or recommendation decisions, and consider referring complex cases to emerging cannabinoid specialists where available, while maintaining awareness that current evidence does not support routine use across most indications.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: